Short Interest in Celularity Inc. (NASDAQ:CELUW) Drops By 84.0%

Celularity Inc. (NASDAQ:CELUW) saw a significant decrease in short interest in January. As of January 30th, there was short interest totaling 542 shares, a decrease of 84.0% from the January 15th total of 3,393 shares. Based on an average trading volume of 22,573 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 22,573 shares, the short-interest ratio is currently 0.0 days.

Celularity Stock Down 10.7%

CELUW stock traded down $0.00 during midday trading on Tuesday, hitting $0.01. The company’s stock had a trading volume of 14,850 shares, compared to its average volume of 17,066. The stock’s 50-day moving average price is $0.02 and its 200 day moving average price is $0.03. Celularity has a 1 year low of $0.01 and a 1 year high of $0.75.

About Celularity

Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.

The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.